P Annovazzi
Overview
Explore the profile of P Annovazzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinelli V, Albanese M, Altieri M, Annovazzi P, Arabi S, Bucello S, et al.
Eur Rev Med Pharmacol Sci
. 2022 Feb;
26(3):935-946.
PMID: 35179760
Objective: Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, disimmune disease of the central nervous system whose etiology and pathogenesis remain poorly understood, due to its complex and multifactorial nature....
2.
Ferraro D, Annovazzi P, Lanzillo R, Calabrese M, Fantozzi R, De Luca G, et al.
J Neurol Sci
. 2021 Apr;
424:117430.
PMID: 33838554
The prevalence of trigeminal neuralgia (TN) in patients with Multiple Sclerosis (MS) is higher than in the general population and its management can be particularly challenging due to a number...
3.
Tortorella C, Solaro C, Annovazzi P, Boffa L, Buscarinu M, Buttari F, et al.
Neurol Sci
. 2020 Apr;
41(8):2249-2253.
PMID: 32240416
In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient's...
4.
Baroncini D, Annovazzi P, Guaschino C, Minonzio G, Hametner S, Stadelmann C, et al.
Mult Scler Relat Disord
. 2020 Mar;
41:102061.
PMID: 32203930
No abstract available.
5.
Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, et al.
J Neurol
. 2018 Jun;
265(8):1850-1859.
PMID: 29948245
Background: Dimethyl-fumarate (DMF) demonstrated efficacy and safety in relapsing-remitting multiple sclerosis (MS) in randomized clinical trials. Objectives: To track and evaluate post-market DMF profile in real-world setting. Materials And Methods:...
6.
Frau J, Sormani M, Signori A, Realmuto S, Baroncini D, Annovazzi P, et al.
Eur J Neurol
. 2018 Jun;
25(10):1270-1275.
PMID: 29851435
Background And Purpose: There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course...
7.
Solaro C, Rezzani C, Trabucco E, Amato M, Zipoli V, Portaccio E, et al.
J Neurol Sci
. 2013 Jun;
331(1-2):94-7.
PMID: 23747002
Objective: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with a chronic course. Dysphagia represents one of the current challenges in clinical practice for the...
8.
Ghezzi A, Annovazzi P, Amato M, Capello E, Cavalla P, Cocco E, et al.
Mult Scler
. 2013 Feb;
19(7):961-3.
PMID: 23380649
Although it is debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients undergo endovascular treatment (ET) of CCSVI. A study is ongoing...
9.
Ghezzi A, Annovazzi P, Cocco E, Coarelli G, Lugaresi A, Rovaris M, et al.
Neurol Sci
. 2013 Jan;
34(9):1633-7.
PMID: 23354606
Although it is still debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients underwent endovascular treatment (ET) of CCSVI. The objective of...
10.
Ghezzi A, Rocca M, Baroncini D, Annovazzi P, Zaffaroni M, Minonzio G, et al.
J Neurol
. 2012 Nov;
260(1):327-9.
PMID: 23161460
No abstract available.